Literature DB >> 29413686

Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.

Yang Deng1, Huakang Tu2, Jeanne A Pierzynski2, Ethan D Miller3, Xiangjun Gu4, Maosheng Huang2, David W Chang2, Yuanqing Ye2, Michelle A T Hildebrandt2, Alison P Klein5, Ren Zhao6, Scott M Lippman7, Xifeng Wu8.   

Abstract

BACKGROUND: Quality of life (QOL) is impaired in pancreatic cancer patients. Our aim was to investigate the determinants and prognostic value of QOL after diagnosis in a hospital-based cohort of racially/ethnically diverse patients with pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: QOL was prospectively assessed using the Short Form-12 in 2478 PDAC patients. The Physical Component Summary (PCS) and Mental Component Summary (MCS) were categorised into tertiles based on their distribution. Ordered logistic regression was adopted to compare the risk of having lower PCS and MCS by patient sociodemographic and clinical characteristics. The association of PCS and MCS with mortality was assessed by Cox regression.
RESULTS: Compared with non-Hispanic whites, Hispanics were at significantly higher risk of having lower PCS (odds ratio [95% CI], 1.69 [1.26-2.26]; P < 0.001) and lower MCS (1.66 [1.24-2.23]; P < 0.001). Patients diagnosed with stage III (1.80 [1.10-2.94]; P = 0.02) and stage IV (2.32 [1.50-3.59]; P < 0.001) PDAC were more likely to have lower PCS than stage I patients. Other determinants of QOL included sex, age, drinking, smoking, education level, comorbidities and time since diagnosis. The low tertile of PCS (hazard ratio [95% CI], 1.94 [1.72-2.18]; P < 0.001) and MCS (1.42 [1.26-1.59]; P < 0.001) were each related to poor prognosis. Similar results were found for non-Hispanic whites as compared with African-Americans/Hispanics/others.
CONCLUSION: QOL after diagnosis is a significant prognostic indicator for patients with PDAC. Multiple factors determine QOL, suggesting possible means of intervention to improve QOL and outcomes of PDAC patients.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Overall survival; Pancreatic ductal adenocarcinoma; Prognostic indicator; Quality of life; Short Form-12

Mesh:

Year:  2018        PMID: 29413686     DOI: 10.1016/j.ejca.2017.12.023

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Health-related quality of life in Malaysian gastrointestinal cancer patients and their family caregivers-a comparison study.

Authors:  Nik Nairan Abdullah; Idayu Badilla Idris; Khadijah Shamsuddin; Nik Muhd Aslan Abdullah
Journal:  Support Care Cancer       Date:  2019-07-29       Impact factor: 3.603

2.  Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.

Authors:  Eve M Roth; Carrie C Lubitz; John Shannon Swan; Benjamin C James
Journal:  Thyroid       Date:  2020-05-14       Impact factor: 6.568

3.  Health-related quality of life and medical comorbidities in older patients with pancreatic adenocarcinoma: An analysis using the 1998-2011 surveillance, epidemiology, and end results-medicare health outcomes survey data.

Authors:  Shan S Wong; Fang-Chi Hsu; Nancy E Avis; Clancy J Clark
Journal:  J Geriatr Oncol       Date:  2019-09-09       Impact factor: 3.929

Review 4.  The Diverse Involvement of Cigarette Smoking in Pancreatic Cancer Development and Prognosis.

Authors:  Simcha Weissman; Kazuki Takakura; Guido Eibl; Stephen J Pandol; Masayuki Saruta
Journal:  Pancreas       Date:  2020 May/Jun       Impact factor: 3.327

Review 5.  Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy.

Authors:  Ramez Kouzy; Joseph Abi Jaoude; Daniel Lin; Nicholas D Nguyen; Molly B El Alam; Ethan B Ludmir; Cullen M Taniguchi
Journal:  Cancers (Basel)       Date:  2020-09-02       Impact factor: 6.639

6.  Exercise Medicine in the Management of Pancreatic Cancer: A Systematic Review.

Authors:  Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe
Journal:  Pancreas       Date:  2021-03-01       Impact factor: 3.243

7.  Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

Authors:  Berta Laquente; Teresa Macarulla; Cristina Bugés; Marta Martín; Carlos García; Carles Pericay; Sandra Merino; Laura Visa; Teresa Martín; Manuela Pedraza; Beatriz Carnero; Raquel Guardeño; Helena Verdaguer; Alejandro Mut; David Vilanova; Adelaida García
Journal:  BMC Palliat Care       Date:  2020-07-10       Impact factor: 3.234

8.  Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus.

Authors:  A Carrato; L Cerezo; J Feliu; T Macarulla; E Martín-Pérez; R Vera; J Álvarez; J I Botella-Carretero
Journal:  Clin Transl Oncol       Date:  2021-08-07       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.